2012 in BPH has been characterized by studies investigating treatment options for BPH-associated lower urinary tract symptoms (LUTS). Onabotulinumtoxin A and saw palmetto have both been shown to be no more effective than placebo. However, in a positive move, tadalafil received FDA approval for LUTS treatment.